Bayer, Ajinomoto, Lady Gaga: Intellectual Property

The U.S. Supreme Court, rebuffing calls to scrutinize “pay for delay” drug settlements, refused to revive a suit accusing Bayer AG of paying almost $400 million to forestall competition to its Cipro antibiotic.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.